Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

Duranay, Murat; Akay, Hatice; Yılmaz, Fatma Meriç; Şeneş, Mehmet; Tekeli, Nurçin; Yücel, Doğan

doi:10.1093/ndt/gfl356

Cited by 81 publications

(65 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Additionally, there was a significant benefit of LC on transferrin, total protein, and albumin levels of the hemodialysis patients. [12] There are also a few reports supporting the hypothesis that treatment with LC can improve chronic inflammation in hemodialysis patients. [13] Lung and kidney function are intimately related in both health and disease.…”

Section: Discussionmentioning

confidence: 99%

The Effects of L-Carnitine Therapy on Respiratory Function Tests in Chronic Hemodialysis Patients

Bavbek

Akay²,

et al. 2010

Renal Failure

View full text Add to dashboard Cite

Background. Respiratory functions are affected during hemodialysis. The strength of respiratory muscles, ultrafiltration rate, and acid-base balance have been suggested as important factors. L-carnitine is crucial for energy producing, utilization of fatty acid, and possible amino acids. A lack of carnitine in hemodialysis patients is caused by insufficient carnitine synthesis and especially by its loss during dialysis. This study was performed to investigate the chronic effects of L-carnitine treatment on respiratory functions in adults receiving chronic hemodialysis therapy. Methods. A total of 20 hemodialysis patients were scheduled to take L-carnitine supplementation (20 mg/kg three times/week) (group 1), and the rest of 20 hemodialysis patients served as the control group and were observed without supplementation with L-carnitine (group 2). Pre-and post-dialytic Lcarnitine levels and post-dialytic respiratory functions tests were performed in both groups at baseline and after six months. Results. The average concentration of free and total carnitine levels increased significantly after six months of supplementation (p < 0.01). While a statistically significant increase between postdialytic forced expiratory volume in one second/forced vital capacity values after treatment period (77.10 ± 12.15 and 83.00 ± 14.49, before and after treatment, respectively, p < 0.05) was observed, the increase of vital capacity, forced expiratory volume in one second, and forced expiratory flow between 25-75% of expired vital capacity were not significant in the treatment group (p > 0.05). Conclusion. Intravenous L-carnitine supplementation could contribute to the management of respiratory dysfunction in chronic hemodialysis patients by improving FEV1/ FVC. The mechanism by which LC causes these effects merits further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

The Effects of L-Carnitine Therapy on Respiratory Function Tests in Chronic Hemodialysis Patients

Bavbek

Akay²,

et al. 2010

Renal Failure

View full text Add to dashboard Cite

show abstract

“…Few studies on the effect of L-carnitine supplement on serum CRP are available, and their results are in agreement with the result of our study. 24,25 A meta-analysis on 31 prospective studies of major CVDs and nonvascular mortality showed that the hazard ratios per 100 mg/dL (or 1 g/L) increase in usual fibrinogen concentration for coronary heart disease and stroke were 2.4 and 2, respectively. 26 Therefore, the reduction of plasma fibrinogen concentration by L-carnitine supplement may play an effective role in reducing the risk of CVD and stroke in hemodialysis patients.…”

Section: Discussionmentioning

confidence: 99%

Effects ofL-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients

et al. 2010

View full text Add to dashboard Cite

Background: Hypercoagulability is an important risk factor for thrombosis and its complications in hemodialysis patients. This study was designed to investigate the effects of L-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. Methods: Thirty-six hemodialysis patients were randomly assigned to either a carnitine or a placebo group. Patients in the carnitine group received 1000 mg/day oral L-carnitine for 12 weeks, whereas patients in the placebo group received a corresponding placebo. At baseline and the end of week 12, 5 mL blood was collected after a 12-to 14-hour fast and plasma fibrinogen concentration, activity of plasma protein C, coagulation factors V, VII, IX, and serum concentrations of tissue plasminogen activator (tPA), plasminogen activator inhibitor type-1 (PAI-1), free carnitine, and C-reactive protein (CRP) were measured. Results: In the carnitine group, mean serum free carnitine concentration increased significantly to 150% of baseline (p < 0.001), whereas plasma fibrinogen and serum CRP had 98 mg/dL (p < 0.01) and 41% (p < 0.01) significant decreases, respectively, at the end of week 12 compared with baseline. The reductions were significant compared with the placebo group (p < 0.05). No significant differences were observed between the two groups with regard to mean changes of the activity of plasma protein C, coagulation factors V, VII, IX, and serum PAI-1 to tPA ratio. Conclusion: L-Carnitine supplement reduces serum CRP, a marker of systemic inflammation, and plasma fibrinogen, an inflammation-related coagulation factor, in hemodialysis patients. Therefore, L-carnitine may play an effective role in preventing cardiovascular diseases in these patients.

show abstract

“…L-carnitine has also been reported to have anti-inflammatory characteristic in previous investigations using animal models (Winter et al, 1995;Vescovo et al, 2002;Idrovo et al, 2012;Liu et al, 2011) and human studies, including patients with type 2 diabetes mellitus (Derosa et al, 2011), nonalcoholic steatohepatitis (Malaguarnera et al, 2010), and coronary artery disease (Lee et al, 2014) and patients undergoing hemodialysis (Shakeri et al, 2010;Duranay et al, 2006;Suchitra et al, 2011). Moreover, our results demonstrated a significant difference between the treatment groups in serum level changes of MMP-3 through the study.…”

Section: Discussionmentioning

confidence: 94%

L-Carnitine supplementation ameliorates serum tumor necrosis factor-alpha and matrix metalloproteinase-3 in knee osteoarthritis women

Mahdavi

Kolahi

Attari

et al. 2017

Bangladesh J Pharmacol

View full text Add to dashboard Cite

<p class="Abstract">Seventy-two females with mild to moderate knee osteoarthritis were included in this randomized double-blind placebo-controlled study. Patients in the intervention group (n=36) received L-carnitine supplement (750 mg/day) for two months. L-Carnitine supplementation led to decrease in serum TNF-α and MMP-3 levels significantly in comparison with the baseline (p<0.001 and p<0.001, respectively) and placebo group (p<0.001 and p=0.03, respectively). In addition, physician’s global assessment of the severity of osteoarthritis decreased significantly in the L-carnitine group (p<0.001) and placebo group (p=0.012) after supplementation. At the end of the study, a significant difference was observed between the two groups for mean physician’s global assessment of the severity of osteoarthritis (p<0.001), adjusted for baseline values and duration of osteoarthritis. L-Carnitine supplementation has beneficial effects in reducing inflammatory biomarkers in knee osteoarthritis patients which subsequently leads to the alleviation of disease symptoms.</p>

show abstract

Effects of L-carnitine infusions on inflammatory and nutritional markers in haemodialysis patients

Abstract: There was a significant benefit of L-carnitine on CRP, transferrin, total protein and albumin levels of the haemodialysis patients.

Cited by 81 publications

References 17 publications

The Effects of L-Carnitine Therapy on Respiratory Function Tests in Chronic Hemodialysis Patients

The Effects of L-Carnitine Therapy on Respiratory Function Tests in Chronic Hemodialysis Patients

Effects ofL-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients

L-Carnitine supplementation ameliorates serum tumor necrosis factor-alpha and matrix metalloproteinase-3 in knee osteoarthritis women

Contact Info

Product

Resources

About